Check out our most popular compounded medications! Get Started
Glipizide 5 mg Slow Release Capsules are compounded with Methocel E4M, a controlled-release polymer. This formulation is designed to gradually release the active ingredient over an extended period, providing sustained therapeutic effects. This slow release mechanism reduces the need for frequent dosing and enhances patient compliance. These capsules are used in the treatment of conditions such as Diabetes Mellitus, Hyperglycemia, Hypoglycemia, Polycystic Ovary Syndrome, and Metabolic Syndrome.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Glipizide 5 mg Slow Release Capsules is a specialized formulation designed to manage type 2 diabetes. This medication functions by stimulating the pancreas to produce more insulin, which aids in the efficient utilization of glucose by the body. The unique feature of this formulation is its slow and steady release of the medication over an extended period, ensuring consistent blood sugar control.
This formulation is compounded with Methocel E4M, a type of controlled-release polymer. This polymer is designed to gradually release the encapsulated medication or active ingredient over an extended period of time. This sustained release offers prolonged therapeutic effects, reduces the frequency of dosing, and improves patient compliance, especially for medications that require a controlled and prolonged release profile.
It is crucial to remember that this medication should be consumed with food and not more than once a day. Regular monitoring of blood sugar levels is necessary to ensure the effectiveness of the medication. It is also important to be aware of potential side effects, which may include nausea, vomiting, diarrhea, and headaches.
Prescribers should note that this formulation is designed to provide a slow and steady release of the medication, allowing for more consistent blood sugar control. Regular monitoring of blood sugar levels is necessary to ensure that the medication is working properly.
If you have any questions about Glipizide 5 mg Slow Release Capsules or its use in the treatment of type 2 diabetes, please do not hesitate to contact us at Bayview Pharmacy. We are here to assist you with your medication needs.
Glipizide 5 mg Slow Release Capsules are formulated with Methocel E4M, a controlled-release polymer, designed to gradually release the encapsulated medication over an extended period. This formulation offers sustained therapeutic effects, reduced dosing frequency, and improved patient compliance for medications requiring a controlled and prolonged release profile. However, these capsules may interact with other medications, including insulin, sulfonylureas, thiazolidinediones, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, phenothiazines, monoamine oxidase inhibitors (MAOIs), and certain antibiotics.
Patients are advised to inform their healthcare provider of all medications they are currently taking, including over-the-counter medications, vitamins, and herbal supplements. Awareness of potential drug-drug and drug-food interactions is crucial. Glipizide 5 mg Slow Release Capsules may increase the risk of hypoglycemia when taken with other medications that lower blood sugar. Therefore, patients should be monitored for signs and symptoms of hypoglycemia and adjust their dose of glipizide accordingly.
Similarly, these capsules may increase the risk of hyperglycemia when taken with other medications that increase blood sugar. Monitoring for signs and symptoms of hyperglycemia and adjusting the dose of glipizide is necessary. The risk of lactic acidosis may also increase when taken with other medications that can cause lactic acidosis. Patients should be monitored for signs and symptoms of lactic acidosis and adjust their dose of glipizide accordingly.
Furthermore, Glipizide 5 mg Slow Release Capsules may increase the risk of hypokalemia when taken with other medications that can cause hypokalemia. Monitoring for signs and symptoms of hypokalemia and adjusting the dose of glipizide is advised. Lastly, these capsules may increase the risk of hyperuricemia when taken with other medications that can cause hyperuricemia. Patients should be monitored for signs and symptoms of hyperuricemia and adjust their dose of glipizide accordingly. If you have any questions, please reach out to your healthcare provider.
Glipizide 5 mg Slow Release Capsules are a specialized oral medication designed to manage type 2 diabetes. The active ingredient, glipizide, functions by augmenting the insulin release from the pancreas, thereby enabling the body to utilize glucose more efficiently. Additionally, glipizide enhances the body's insulin response, contributing to the reduction of blood sugar levels.
The unique slow-release formulation of these capsules, achieved through the use of Methocel E4M, a controlled-release polymer, ensures a gradual release of the medication over an extended period. This sustained release profile allows for a consistent level of the drug in the body, facilitating better control of blood sugar levels, reducing the frequency of dosing, and improving patient compliance.
When using Glipizide 5 mg Slow Release Capsules, adherence to the prescribed dosage by your healthcare provider is crucial. Typically, the capsules are taken with food once daily. Consistency in the timing of medication intake each day is important to maintain a steady level of the drug in the body.
If you have any queries or require further clarification about Glipizide 5 mg Slow Release Capsules, please do not hesitate to reach out. Our goal is to help you understand the workings of this medication and how it can assist you in managing your type 2 diabetes effectively.
Glipizide 5 mg Slow Release Capsules are a versatile medication, primarily used in the management of type 2 diabetes. The slow-release formulation, designed with Methocel E4M, ensures a controlled and prolonged release of the active ingredient, offering sustained therapeutic effects and improved patient compliance. This formulation can also be beneficial in managing gestational diabetes and insulin resistance.
These capsules can also play a significant role in reducing the risk of cardiovascular disease in patients with type 2 diabetes. For patients with prediabetes, Glipizide 5 mg Slow Release Capsules can be used as a preventive measure to reduce the risk of developing type 2 diabetes, polycystic ovary syndrome in women, and metabolic syndrome.
Furthermore, Glipizide can be used to manage the risk of hypoglycemia and hyperglycemia in patients with diabetes. It can also be instrumental in reducing the risk of developing complications associated with diabetes, such as retinopathy, nephropathy, and neuropathy.
If you have any questions about the use of Glipizide 5 mg Slow Release Capsules for any of these conditions, please do not hesitate to reach out for further information.
Glipizide 5 mg Slow Release Capsules is a medication that is encapsulated in a controlled-release polymer, Methocel E4M. This formulation is designed to gradually release the active ingredient over an extended period of time.
Methocel E4M is a type of controlled-release polymer. It is used in the formulation to ensure that the medication is released gradually over an extended period of time, offering sustained therapeutic effects.
The benefits of using Glipizide 5 mg Slow Release Capsules include sustained therapeutic effects, reduced dosing frequency, and improved patient compliance. This is particularly beneficial for medications requiring a controlled and prolonged release profile.
The slow release mechanism works by gradually releasing the encapsulated medication over an extended period of time. This is achieved through the use of a controlled-release polymer, Methocel E4M, in the formulation.
The dosing frequency of Glipizide 5 mg Slow Release Capsules is reduced due to its slow release formulation. However, the exact frequency should be determined by your healthcare provider based on your specific medical condition and response to treatment.
'Improved patient compliance' means that patients are more likely to take their medication as prescribed. This is because the slow release formulation reduces the frequency of dosing, making it more convenient for patients.
No, Glipizide 5 mg Slow Release Capsules should not be broken or chewed. Doing so can release all of the drug at once, increasing the risk of side effects. The capsule should be swallowed whole.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
Side effects can vary from person to person and may include nausea, diarrhea, and upset stomach. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Before starting Glipizide 5 mg Slow Release Capsules, tell your doctor or pharmacist of all the products you use. This includes prescription drugs, nonprescription drugs, and herbal products. They can provide guidance on potential interactions.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth
